InvestorsHub Logo
Followers 87
Posts 6669
Boards Moderated 1
Alias Born 09/18/2009

Re: None

Tuesday, 01/09/2024 12:10:22 AM

Tuesday, January 09, 2024 12:10:22 AM

Post# of 42837
I wonder if Durrant will buy either the London or Dublin subsidiary, or, with a good chance of Regulatory Approval in Australia, maybe he'll buy that subsidiary.

https://www.humanigen.com/subsidiaries

Regardless, it appears that he may be buying the equity one of them.

I need to point out that there is an Item 7.01 Regulation FD Disclosure which states, "The Company expects that holders of shares of the Company’s common stock will experience a complete or significant loss on their investment, depending on the outcome of the Chapter 11 Case." We pretty much did that, already.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465924000421/o152468k.htm

However, a long range plan is in place for Taran (Durrant's Therapeutic company) to pay "...$20 million, comprised of $2 million in cash at closing of the Transaction and up to $18 million in milestone payments in cash..." spread out over a 5 - 7 year time frame. This obviously indicates that the company anticipates to survive as a going concern.

I'm pointing out what has been filed. But at the same time, I think the concern will prove moot, as it appears to me that we are prepared to repeat our history, and issue a second recall of our loaned shares.